- Home
- NMT vs ACRS Comparison
NMT vs ACRS Comparison
Compare NMT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- ACRS
- Stock Information
- Founded
- NMT 1993
- ACRS 2012
- Country
- NMT United States
- ACRS United States
- Employees
- NMT N/A
- ACRS N/A
- Industry
- NMT Finance/Investors Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- ACRS Health Care
- Exchange
- NMT Nasdaq
- ACRS Nasdaq
- Market Cap
- NMT 110.6M
- ACRS 127.6M
- IPO Year
- NMT N/A
- ACRS 2015
- Fundamental
- Price
- NMT $11.96
- ACRS $1.26
- Analyst Decision
- NMT
- ACRS Strong Buy
- Analyst Count
- NMT 0
- ACRS 7
- Target Price
- NMT N/A
- ACRS $10.67
- AVG Volume (30 Days)
- NMT 19.1K
- ACRS 801.8K
- Earning Date
- NMT 01-01-0001
- ACRS 05-08-2025
- Dividend Yield
- NMT 3.21%
- ACRS N/A
- EPS Growth
- NMT N/A
- ACRS N/A
- EPS
- NMT N/A
- ACRS N/A
- Revenue
- NMT N/A
- ACRS $17,777,000.00
- Revenue This Year
- NMT N/A
- ACRS N/A
- Revenue Next Year
- NMT N/A
- ACRS $425.96
- P/E Ratio
- NMT N/A
- ACRS N/A
- Revenue Growth
- NMT N/A
- ACRS N/A
- 52 Week Low
- NMT $9.05
- ACRS $0.95
- 52 Week High
- NMT $10.93
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- NMT 64.72
- ACRS 43.64
- Support Level
- NMT $11.65
- ACRS $1.20
- Resistance Level
- NMT $11.86
- ACRS $1.46
- Average True Range (ATR)
- NMT 0.17
- ACRS 0.11
- MACD
- NMT 0.05
- ACRS 0.02
- Stochastic Oscillator
- NMT 100.00
- ACRS 41.77
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.